Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Intellia Therapeutics Pooled Phase 1/2 Data Show 97% Of Patients Attack-Free And LTP-Free After One-Time 50mg Dose Of Lonvoguran Ziclumeran In Hereditary Angioedema

Author: Benzinga Newsdesk | November 10, 2025 03:56am

Deep, stable and durable reductions in kallikrein observed
Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff:
- 31 (97%) were attack-free and long-term prophylaxis (LTP)-free
- 24 (75%) were attack-free and LTP-free for at least seven months (up to 32 months)
- Among the 11 patients who originally received a 50 mg dose in Phase 2, 10 were attack-free and LTP-free
Continue to observe a well-tolerated safety profile with up to three years of patient follow-up and no new long-term risks identified

Posted In: NTLA